Revenue and gross margin: QQ4 2024 revenue of $76,110 with gross profit of -$12,685, yielding a gross margin of -16.7%. Management reported ongoing R&D and G&A expenditures (R&D $183,430; G&A $666,635) leading to total operating expenses of $837,379 and an operating loss of $850,064. Net income for the quarter was -$851,529 and earnings per share (EPS) was -$1.24. YoY and QoQ revenue changes are not disclosed in a way that allows a clean year-over-year comparison for the exact quarter; the reported metrics indicate continued negative profitability characteristic of early-stage biotech.
Profitability and margins: The company posted negative EBITDA of -$837,380 and an EBITDAR ratio of approximately -11.00 (as reported). The net income margin stands at about -11.19%, and the operating income margin is -11.17%. The strong SG&A component relative to revenue is the primary driver of the operating loss. Although the stock is pre-revenue, the line items reflect the immaterial top-line that comes with a Phase II-stage biotech.
Cash flow and liquidity: Cash flow from operating activities was -$1,426,707 for QQ4 2024. Investing activities used $147,243 in PPE and other investments, while financing activities generated $1,519,888, producing a net cash increase of $93,181. The company ended the period with $376,048 in cash and cash equivalents and total debt of $300,714. Net debt stood at -$75,334, reflecting a cash position that is modest relative to the ongoing cash burn. Free cash flow was -$1,279,464, underscoring the funding gap that financing is attempting to fill on a quarterly basis.
Balance sheet and capitalization: Total assets were $631,588, with current assets at $455,242 and total current liabilities of $3,225,773. Liabilities exceed assets by a wide margin, and stockholders’ equity sits at approximately -$2,594,185. Deferred revenue is negative at -$2,925,059, which may reflect timing differences in grant or collaboration funding versus revenue recognition. The company carries a short-term debt burden of $300,714 and does not report long-term debt in the period, suggesting a liquidity profile that is dependent on ongoing financing to meet near-term obligations.